2 active not recruiting, 2 completed, 1 enrolling by invitation. 4 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Enrolling by invitation 1 |
| Phase 3 | 2 | Active not recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow RGX-314: new trials by email Literature Review of RGX-314 trials Research Report on RGX-314
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) RGX-314 - Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | Phase 2 | Completed | AbbVie | 60 | 2021-02-22 | 2024-09-05 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
| Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy RGX-314 - Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | Phase 2 | Enrolling by invitation | AbbVie | 865 | 2019-05-31 | 2024-06-17 |
| Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial RGX-314 - Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | REGENXBIO Inc. | 42 | 2017-03-29 | 2023-05-16 |
Wet Macular Degeneration (4) · Choroidal Neovascularization (2) · Eye Diseases (2) · Macular Degeneration (2) · Retinal Degeneration (2) · Retinal Diseases (2)
AbbVie (4) · REGENXBIO Inc. (1)
United States (5) · Canada (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)